Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05029141 | New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 21 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07458542 | Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia | active not recruiting | — | 44 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04460963 | Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches | active not recruiting | N/A | 72 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05306301 | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | active not recruiting | Phase 2 | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program(DARATALL-VHR) | active not recruiting | Phase 2 | 31 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies(Orca-T) | active not recruiting | Phase 3 | 187 | Orca Biosystems, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04263181 | AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration | active not recruiting | — | 80 | Washington University School of MedicineOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07437170 | Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | active not recruiting | Phase 2 | 10 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02339740 | Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia | active not recruiting | Phase 3 | 158 | Children's Oncology GroupNETWORK | 6 | Feb 18, 2026 | clinicaltrials |
| NCT06325748 | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | active not recruiting | Phase 1 | 21 | Senti BiosciencesINDUSTRY | 2 | Feb 12, 2026 | clinicaltrials |
| NCT05197426 | A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission | active not recruiting | Phase 2 | 19 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 11, 2026 | clinicaltrials |
| NCT03735797 | Cancer Stem Cells in Acute Leukemia | active not recruiting | — | 50 | Sanford HealthOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT00586391 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL(CRETI-NH) | active not recruiting | Phase 1 | 14 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | active not recruiting | Phase 2 | 150 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03701308 | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | active not recruiting | Phase 2 / Phase 3 | 267 | National Cancer Institute (NCI)NIH | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | active not recruiting | Phase 1 | 38 | Polaris GroupINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03987958 | A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)(REVIVE) | active not recruiting | — | 100 | AbbVieINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML(AML) | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05942599 | Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation(CARAML) | active not recruiting | Phase 1 | 10 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06572982 | Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients | active not recruiting | N/A | 20 | Hikma Pharmaceuticals LLCINDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03121014 | Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | active not recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04203316 | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | active not recruiting | Phase 2 | 1 | Children's Oncology GroupNETWORK | 2 | Jan 9, 2026 | clinicaltrials |
| NCT04928599 | Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States | active not recruiting | — | 100 | Children's Oncology GroupNETWORK | 2 | Jan 8, 2026 | clinicaltrials |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | active not recruiting | Phase 2 | 22 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03912064 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | active not recruiting | Phase 1 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05199051 | A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML(AGORA-1) | active not recruiting | Phase 2 | 19 | Centre Antoine LacassagneOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07269587 | A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19 | active not recruiting | — | 275 | Ruijin HospitalOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04167683 | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | active not recruiting | — | 144 | Rigshospitalet, DenmarkOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT02483312 | A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML) | active not recruiting | Phase 1 | 9 | University Health Network, TorontoOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07238907 | A Multi-center Retrospective Study of INO Treating B-ALL | active not recruiting | — | 102 | Ruijin HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT03233854 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | active not recruiting | Phase 1 | 56 | Stanford UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07232953 | Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia(FT14) | active not recruiting | Phase 2 | 82 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)(CARPASCIO) | active not recruiting | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04060277 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | active not recruiting | Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04684563 | huCART19-IL18 in CD19+ Cancers | active not recruiting | Phase 1 | 72 | University of PennsylvaniaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04817241 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | active not recruiting | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04148430 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | active not recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05236764 | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion(HAPLOTAB) | active not recruiting | N/A | 3 | Baylor College of MedicineOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT02756962 | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | active not recruiting | Phase 2 | 107 | Washington University School of MedicineOTHER | 1 | Oct 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 25, 2026source: clinicaltrials